Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls

Rögnvaldsson, Sæmundur; Steingrímsson, Vilhjálmur; Turesson, Ingemar; Björkholm, Magnus; Landgren, Ola; Kristinsson, Sigurður Y.

doi:10.3324/haematol.2019.239632

Cited by 17 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Peripheral neuropathy is the most frequent neurological syndrome associated with monoclonal gammopathies [56]. By far, the association is stronger and more frequent when the IgM isotype is involved (related to either IgM MGUS or Waldenström macroglobulinemia) [21].…”

Section: Neurologic M-protein Diseases Igm Peripheral Neuropathymentioning

confidence: 99%

Treatment of Patients with Monoclonal Gammopathy of Clinical Significance

Moreno

Rosiñol

Cibeira

et al. 2021

Cancers

View full text Add to dashboard Cite

Monoclonal gammopathy of undetermined significance (MGUS) is defined as the presence of a monoclonal protein (M-protein) produced by a small amount of plasma cells. The majority of patients remain asymptomatic; however, a fraction of them develop clinical manifestations related to the monoclonal gammopathy despite not fulfilling criteria of multiple myeloma or other lymphoproliferative disorder. These patients constitute an emerging clinical issue coined as monoclonal gammopathy of clinical significance (MGCS). The mechanisms involved are poorly understood, and literature is scarce regarding management. The clinical spectrum involves symptoms related to renal, neurologic, skin, ocular, or bleeding manifestations, requiring a multidisciplinary approach. Treatment strategies rely on the basis of symptomatic disease and the M-protein isotype. In this review, we focus on MGCS other than renal, as the latter was earliest recognized and better known. We review the literature and discuss management from diagnosis to treatment based on illustrative cases from daily practice.

show abstract

Section: Neurologic M-protein Diseases Igm Peripheral Neuropathymentioning

confidence: 99%

Treatment of Patients with Monoclonal Gammopathy of Clinical Significance

Moreno

Rosiñol

Cibeira

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Large series have demonstrated that patients with MGUS have a fourfold increase in risk for PN (greater than that of diabetes) and is likely underdiagnosed. 28 The majority of MGUS patients have an immunoglobulin G (IgG) kappa. Monoclonal gammopathy-associated PN, however, is most commonly seen in patients with IgM kappa gammopathy.…”

Section: Monoclonal Gammopathymentioning

confidence: 99%

Neuropathy of Connective Tissue Diseases and Other Systemic Diseases

Jin

Shin

2019

Semin Neurol

View full text Add to dashboard Cite

Peripheral neuropathy is associated with numerous systemic diseases. It is often the heralding finding, which can lead to earlier diagnoses and better outcomes. An understanding of the epidemiology and clinical features of these diseases is paramount to their diagnosis and management. This article will focus on neuropathy associated with connective tissue diseases, monoclonal gammopathies, paraneoplastic disorders, medications including chemotherapeutic agents, nutritional deficiencies, alcohol, and toxins.

show abstract

“…A large cohort study from Scandinavia has found that peripheral neuropathy was associated with an almost three-fold increase in the risk of light chain amyloidosis. [52]. The neuropathy of amyloidosis frequently presents with painful sensory symptoms or autonomic dysfunction, and nerve conduction studies often reveal an axonal pattern that helps to differentiate from the demyelinating phenotype observed in IgM-MGUS neuropathy.…”

Section: Peripheral Neuropathymentioning

confidence: 99%

“…The association between monoclonal paraproteinemia and neuropathy has been demonstrated in a population-based screening study, which found a higher than expected prevalence of peripheral neuropathy [ 10 ]. A retrospective analysis of a large Scandinavian cohort has found an approximately three-fold increase in the relative risk for peripheral neuropathy in cases of MGUS, independently of diabetes mellitus [ 52 ]. The absolute prevalence of peripheral neuropathy appears to be under 5% of MGUS patients [ 53 ].…”

Section: Peripheral Neuropathymentioning

confidence: 99%

Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All

Lomas

Mouhieddine

Tahri

et al. 2020

Cancers

View full text Add to dashboard Cite

Monoclonal Gammopathy of Undetermined Significance (MGUS) is considered to be a benign precursor condition that may progress to a lymphoproliferative disease or multiple myeloma. Most patients do not progress to an overt condition, but nevertheless, MGUS is associated with a shortened life expectancy and, in a minority of cases, a number of co-morbid conditions that include an increased fracture risk, renal impairment, peripheral neuropathy, secondary immunodeficiency, and cardiovascular disease. This review aims to consolidate current evidence for the significance of these co-morbidities before considering how best to approach these symptoms and signs, which are often encountered in primary care or within a number of specialties in secondary care.

show abstract

Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls

Cited by 17 publications

References 14 publications

Treatment of Patients with Monoclonal Gammopathy of Clinical Significance

Treatment of Patients with Monoclonal Gammopathy of Clinical Significance

Neuropathy of Connective Tissue Diseases and Other Systemic Diseases

Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All

Contact Info

Product

Resources

About